Stifel Financial’s Recursion Pharmaceuticals RXRX Stock Holding History

Stifel Financial’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.23M	Buy	881,457 +104,529	+13%	+$348K	﹤0.01%	1706
2026 Q1	$2.39M	Buy	776,928 +186,780	+32%	+$722K	﹤0.01%	1837
2025 Q4	$2.41M	Buy	590,148 +147,353	+33%	+$730K	﹤0.01%	1801
2025 Q3	$2.16M	Buy	442,795 +186,703	+73%	+$980K	﹤0.01%	1854
2025 Q2	$1.3M	Buy	256,092 +68,833	+37%	+$338K	﹤0.01%	2151
2025 Q1	$991K	Buy	187,259 +27,372	+17%	+$200K	﹤0.01%	2239
2024 Q4	$1.08M	Sell	159,887 -2,091	-1%	-$14.1K	﹤0.01%	2199
2024 Q3	$1.07M	Buy	161,978 +53,103	+49%	+$381K	﹤0.01%	2186
2024 Q2	$817K	Buy	108,875 +64,466	+145%	+$562K	﹤0.01%	2309
2024 Q1	$443K	Buy	44,409 +17,220	+63%	+$192K	﹤0.01%	2688
2023 Q4	$268K	Buy	+27,189	New	+$194K	﹤0.01%	2907

Other funds holding RXRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Stifel Financial's RXRX Position: Q2 2026 in Review

Stifel Financial increased its Recursion Pharmaceuticals (RXRX) stake by 13% in Q2 2026, buying an estimated $348K and bringing the position to 881,457 shares worth $3.23M. The position accounts for ﹤0.01% of the portfolio, ranked #1706.

Stifel Financial first reported a position in RXRX in Q4 2023 and has held it in 11 quarters since. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

Stifel Financial held 881,457 shares of Recursion Pharmaceuticals worth $3.23M as of Q2 2026.
Stifel Financial bought 104,529 Recursion Pharmaceuticals shares in Q2 2026, an estimated $348K.
Recursion Pharmaceuticals made up ﹤0.01% of Stifel Financial's portfolio in Q2 2026, its #1706 holding.
Stifel Financial first reported a position in Recursion Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Stifel Financial's 13F filing for Q2 2026, filed 12 Aug 2026.